Genomictree Q1 2026 Revenue Up 20.6%, Obtains Bladder Cancer Diagnostic Approval

Q1 2026 consolidated revenue KRW 0.38 billion (+20.6% YoY), operating loss narrowed to KRW 3.03 billion (from KRW 3.73 billion)
EarlyTect Bladder Cancer received MFDS Class III approval and CE-IVDR certification in Jan 2026; Colon cancer product also obtained CE-IVDR
All KRW 5 billion of 1st CB converted into common shares (Q1 2026), eliminating debt and strengthening capital
Disposal of 27,033 treasury shares and approval of treasury share acquisition plan at March 2026 AGM (shareholder return policy)
R&D expenses KRW 0.70 billion (182.5% of sales); prostate cancer exploratory trial ongoing, lung cancer upgraded product development completed
Financial soundness: consolidated debt ratio 2.0%, cash equivalents KRW 8.7 billion, total equity KRW 123.5 billion

ADVERTISEMENT (250px+)